Cardiotoxin Analog (CTX) IV (6-12) TFA

Name: Cardiotoxin Analog (CTX) IV (6-12) TFA
Brand: MedChemExpress
SKU: HY-P1902A
Rating: 5.0 (10 reviews)

Cat. No.: HY-P1902A Purity: 99.58%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Cardiotoxin Analog (CTX) IV (6-12) TFA is a membrane active peptide that specifically targets negatively charged phospholipid membranes (such as phosphatidylserine and phosphatidylinositol). Cardiotoxin Analog (CTX) IV (6-12) TFA was discovered in the venom of the Taiwan cobra. Cardiotoxin Analog (CTX) IV (6-12) TFA is a chemically synthesized snake venom cardiotoxin that binds to cell membranes and embeds into lipid bilayers through hydrophobic interactions and electrostatic attraction, thereby destroying the stability of membrane structure. Cardiotoxin Analog (CTX) IV (6-12) TFA can induce membrane lipid disorder and cell lysis, exhibiting hemolysis and cytotoxicity.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

CAS No. : 2918768-05-3

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 10 publication(s) in Google Scholar

Other Forms of Cardiotoxin Analog (CTX) IV (6-12) TFA:

Cardiotoxin Analog (CTX) IV (6-12) In-stock

10 Publications Citing Use of MCE Cardiotoxin Analog (CTX) IV (6-12) TFA

Histological Imaging/Staining

RT-PCR

: Cardiotoxin Analog (CTX) IV (6-12) TFA purchased from MedChemExpress. Usage Cited in: Mol Ther. 2026 Jan 2:S1525-0016(25)01139-6. [Abstract]; CTRP1 protein levels were analyzed by immunoblotting in the triceps surae of 7-week-old WT mice 5 days after injection with 10 μM Cardiotoxin Analog (CTX) IV (6-12) (i.m.) (top, n = 3). CTRP1 protein levels in the CTX-injected gastrocnemius muscle (left hindlimb) were compared with those in the contralateral control gastrocnemius muscle injected with the vehicle alone (right hindlimb) and normalized using β-actin as a loading control (bottom). CTRP1 protein expression increased approximately 3.3-fold in the gastrocnemius muscle on day 5 post-CTX injection compared to that in the contralateral vehicle (Veh)-injected muscle.

: Cardiotoxin Analog (CTX) IV (6-12) TFA purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 31:e12354. [Abstract]; Representative H&E‐stained sections of Cardiotoxin Analog (CTX) IV (6-12) (10 µM; 100 µL; i.m.)‐injured muscle regeneration at multiple time points in M─KI and WT mice. The scale bars represent 100 µm.

: Cardiotoxin Analog (CTX) IV (6-12) TFA purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 31:e12354. [Abstract]; Representative immunofluorescence images of eMyHC (red) in Cardiotoxin Analog (CTX) IV (6-12) (10 µM; 100 µL; i.m.)‐injured muscles at 14 Dpi. The scale bars represent 100 µm.

: Cardiotoxin Analog (CTX) IV (6-12) TFA purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 31:e12354. [Abstract]; Quantitative analysis of migration markers in Cardiotoxin Analog (CTX) IV (6-12) (10 µM; 100 µL; i.m.)‐injured regenerating muscles was performed at the mRNA level (RT‐qPCR).

: Cardiotoxin Analog (CTX) IV (6-12) TFA purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 31:e12354. [Abstract]; Quantitative analysis of migration markers in Cardiotoxin Analog (CTX) IV (6-12) (10 µM; 100 µL; i.m.)‐injured regenerating muscles was performed at protein (Western blot) levels.

: Cardiotoxin Analog (CTX) IV (6-12) TFA purchased from MedChemExpress. Usage Cited in: Commun Biol. 2022 Nov 9;5(1):1201. [Abstract]; CTX (Cardiotoxin Analog) (10.13 mg/kg; inject into the tibialis anterior (TA) muscle of mice) induces muscle regeneration. H&E staining of the injured TA muscles collected from the designated time points after CTX injection to visualise the degree of regeneration. At d10 after injury, the TA muscle is composed of degenerating myofibers, fibrotic tissues and inflammatory cells.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Cardiotoxin Analog (CTX) IV (6-12) TFA (10 μM; real-time monitoring) shows that after binding to phosphatidylserine (PS)/phosphatidylinositol (PI) vesicles, the fluorescence emission peak blue-shifted to 335 nm and the intensity increases significantly, indicating specific binding to negatively charged lipid membranes^[1].
Cardiotoxin Analog (CTX) IV (6-12) TFA (25 μM; incubation at 37°C) causes complete hemolysis of erythrocytes, possibly inducing cell lysis by disrupting membrane structure^[1].
Cardiotoxin Analog (CTX) IV (6-12) TFA-derived peptide (5-6 μM; 25°C) shifts and enhances its tryptophan fluorescence peak when it bound to negatively charged lipids, which may be related to its binding to the membrane through the N-terminal hydrophobic loop (position 6-12)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

Cardiotoxin (i.m.) induces muscle injury at days 1 to 2 after injection, where inflammatory cells infiltrate and SCs are activated to proliferate. Myoblast differentiation typically occurs at days 3-5. The new fibers with a central nucleus begin to form at days 5-7. The major muscle structures are restored at days 10-14. The damaged muscles have almost completely recovered at day 28^[3]^[4]^[5].
Cardiotoxin induces muscle injury and regeneration, as the destruction, repair and remodeling phase were clearly distinguishable at day 2, day 5 and day 12, respectively^[6].

Induction of Skeletal Muscle Injury^[6]^[7]^[8]

Background

Cardiotoxin affects membrane calcium binding sites, and reduces the threshold of calcium-modulated calcium ion release from the sarcoplasmic reticulum, thereafter inducing the destruction of skeletal muscle^[9].

Specific Modeling Methods

1.Mice: C57BL mice • male • 8-week-old
Administration: Cardiotoxin (10 μM, 20 μL) • i.m. • single dose;
2.Mice: C57BL/6 mice • male •10-week-old
Administration: Cardiotoxin (10 μM, 150 μL) • i.m. • single dose;
3.Mice: C3H/HeNJcl mice • male •8-week-old
Administration: Cardiotoxin (10 μM, 50 μL) • i.m. • single dose;

Note

(1) The injection of Cardiotoxin into the tibialis anterior muscle should be performed slowly to avoid mechanical damage.

Modeling Indicators

Molecular changes: Increased TNF-α, IL-6 level.
Increased Pax7, MyoD, MyoG, and MyHC level.
Histology analysis: Myofibrinolysis, inflammatory infiltration, new myofibril formation, and basic myofibril repair completed (H&E staining).

Correlated Product(s): Cardiotoxin Analog (CTX) IV (6-12) (HY-P1902); Cardiotoxin Analog (CTX) IV (6-12) TFA (HY-P1902A)

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

1013.16

Formula

C₅₀H₇₁F₃N₁₀O₉

CAS No.

2918768-05-3

Appearance

Solid

Color

White to off-white

Sequence

Leu-Ile-Pro-Pro-Phe-Trp-Lys-NH2

Sequence Shortening

LIPPFWK-NH2

Structure Classification

Initial Source

Animals

the venom of Taiwan Cobra

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H₂O : 50 mg/mL (49.35 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.9870 mL	4.9351 mL	9.8701 mL
5 mM	0.1974 mL	0.9870 mL	1.9740 mL
10 mM	0.0987 mL	0.4935 mL	0.9870 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 100 mg/mL (98.70 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.58%

Select Batch:

Data Sheet (290 KB) SDS (252 KB)

COA (262 KB) RP-HPLC (266 KB) MS (70 KB)

Handling Instructions (2659 KB)

References

[1]. Kaneda N, et al. The amino acid sequence of cardiotoxin-analogue IV from the venom of Naja naja atra. FEBS Lett. 1976 Nov;70(1):217-22. [Content Brief]

[2]. Dufourcq J, et al. Structure-function relationships for cardiotoxins interacting with phospholipids. Toxicon. 1982;20(1):165-74. [Content Brief]

[3]. Aoki Y, et al. Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice. Hum Mol Genet. 2013 Dec 15;22(24):4914-28. [Content Brief]

[4]. Randazzo D, et al. Persistent upregulation of the β-tubulin tubb6, linked to muscle regeneration, is a source of microtubule disorganization in dystrophic muscle. Hum Mol Genet. 2019 Apr 1;28(7):1117-1135. [Content Brief]

[5]. Fan W, et al. Hsp70 Interacts with Mitogen-Activated Protein Kinase (MAPK)-Activated Protein Kinase 2 To Regulate p38MAPK Stability and Myoblast Differentiation during Skeletal Muscle Regeneration. Mol Cell Biol. 2018 Nov 28;38(24):e00211-18. [Content Brief]

[6]. Dalle S, et al. Cardiotoxin-induced skeletal muscle injury elicits profound changes in anabolic and stress signaling, and muscle fiber type composition. J Muscle Res Cell Motil. 2020 Dec;41(4):375-387. [Content Brief]

[7]. Liu Y, et al. MicroRNA-200c-5p Regulates Migration and Differentiation of Myoblasts via Targeting Adamts5 in Skeletal Muscle Regeneration and Myogenesis. Int J Mol Sci. 2023 Mar 5;24(5):4995. [Content Brief]

[8]. Mahdy MA, et al. Comparative study of muscle regeneration following cardiotoxin and glycerol injury. Ann Anat. 2015 Nov;202:18-27. [Content Brief]

[9]. Wang Y, et al. Skeletal Muscle Regeneration in Cardiotoxin-Induced Muscle Injury Models. Int J Mol Sci. 2022 Nov 2;23(21):13380. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O	1 mM	0.9870 mL	4.9351 mL	9.8701 mL	24.6753 mL
	5 mM	0.1974 mL	0.9870 mL	1.9740 mL	4.9351 mL
	10 mM	0.0987 mL	0.4935 mL	0.9870 mL	2.4675 mL
	15 mM	0.0658 mL	0.3290 mL	0.6580 mL	1.6450 mL
	20 mM	0.0494 mL	0.2468 mL	0.4935 mL	1.2338 mL
	25 mM	0.0395 mL	0.1974 mL	0.3948 mL	0.9870 mL
	30 mM	0.0329 mL	0.1645 mL	0.3290 mL	0.8225 mL
	40 mM	0.0247 mL	0.1234 mL	0.2468 mL	0.6169 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.